6533b827fe1ef96bd1285c43

RESEARCH PRODUCT

Immunosuppressant therapy of thyroid eye disease.

G KahalyJ. Beyer

subject

Immunosuppression TherapyCyclophosphamidebusiness.industrymedicine.medical_treatmentEye diseaseThyroidAzathioprineGeneral MedicineDiseasemedicine.diseaseeye diseasesGraves DiseaseRadiation therapymedicine.anatomical_structureAutoimmune ProcessDrug DiscoveryImmunologymedicineMolecular MedicineHumansPlasmapheresisbusinessGenetics (clinical)Immunosuppressive Agentsmedicine.drug

description

Thyroid eye disease is attributed to an autoimmune process where both cellular and humoral immunity play a role. In this report, after a short introduction dealing with immunopathogenesis of the disease, immunosuppressant therapy is discussed. Treatment with glucocorticoids (as the standard substance), nonsteroid immunosuppressants (azathioprine, cyclophosphamide, lately cyclosporin) and with the immunomodulatory substance ciamexone is reviewed. Retroorbital irradiation as a "local" immunosuppressive method and plasmapheresis are also discussed. While systemic glucocorticoids and to a lesser extent orbital radiotherapy are routinely administered for severe Graves' ophthalmopathy, nonsteroid immunosuppressants and plasmapheresis are not yet part of the established treatment of thyroid eye disease. Their use should currently remain confined to controlled studies.

10.1007/bf01711917https://pubmed.ncbi.nlm.nih.gov/3070148